Serum qAnti-HBc combined with ALT and HBsAg predicts significant hepatic inflammation in HBeAg-positive immune active patients.

Xiaomei WangXiuzhu GaoRuihong Wu Xiumei Chi Hongqin XuYazhe GuanQinglong Jin Junqi Niu

Published in: Journal of gastroenterology and hepatology (2022)

Serum qAnti-HBc levels were positively correlated with hepatic inflammation grades before treatment, but no positive correlation between them was observed after 48-week treatment. The level of qAnti-HBc combined with ALT and HBsAg may serve as a more reliable marker for identifying significant liver inflammation before treatment in HBeAg-positive immune active patients.

Keyphrases

hepatitis b virus
end stage renal disease
oxidative stress
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
peritoneal dialysis